Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
NICE Recommends BioCryst's Hereditary Angioedema Med
11:50am, Thursday, 16'th Sep 2021
The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recomm
NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
08:20pm, Wednesday, 15'th Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's (UK) National Institute for Health and Care Exc
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
05:05am, Monday, 13'th Sep 2021
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
BioCryst to Present at Upcoming Investor Conferences
07:00am, Friday, 03'rd Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Virtual Wells Fargo Healthcare C
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 02'nd Sep 2021
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
09:03am, Wednesday, 01'st Sep 2021
The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Rapivab (peramivir injection
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised
BioCryst Appoints Dr. Steven Galson to Board of Directors
07:00am, Thursday, 26'th Aug 2021
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Ad
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
04:01pm, Wednesday, 25'th Aug 2021
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accept
2 Soaring Biotech Stocks With More Fuel in the Tank
06:47am, Monday, 23'rd Aug 2021
These recent winners still have a long way to run.
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
08:08am, Wednesday, 11'th Aug 2021
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says that it is well-capitalized, with cash
BioCryst Withdraws Public Offering
06:55pm, Tuesday, 10'th Aug 2021
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it has withdrawn its proposed public offering. With our strong balanc
Why BioCryst Pharmaceuticals Rose 8% on Thursday
04:08pm, Thursday, 05'th Aug 2021
The company's first commercial drug launch keeps exceeding expectations.
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
03:13pm, Thursday, 05'th Aug 2021
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
02:58pm, Thursday, 05'th Aug 2021
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of $50 million, with $28.5 m
